Literature DB >> 22004686

Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction.

John Logan Black1, Denise L Walker, Dennis J O'Kane, Maria Harmandayan.   

Abstract

Cytochrome P450 2D6 (CYP2D6) is highly polymorphic. CYP2D6-2D7 hybrid genes can be present in samples containing CYP2D6*4 and CYP2D6*10 alleles. CYP2D7-2D6 hybrid genes can be present in samples with duplication signals and in samples with homozygous genotyping results. The frequency of hybrid genes in clinical samples is unknown. We evaluated 1390 samples for undetected hybrid genes by polymerase chain reaction (PCR) amplification, PCR fragment analysis, TaqMan copy number assays, DNA sequencing, and allele-specific primer extension assay. Of 508 CYP2D6*4-containing samples, 109 (21.5%) harbored CYP2D6*68 + *4-like, whereas 9 (1.8%) harbored CYP2D6*4N + *4-like. Of 209 CYP2D6*10-containing samples, 44 (21.1%) were found to have CYP2D6*36 + *10. Of 332 homozygous samples, 4 (1.2%) harbored a single CYP2D7-2D6 hybrid, and of 341 samples with duplication signals, 25 (7.3%) harbored an undetected CYP2D7-2D6 hybrid. Phenotype before and after accurate genotyping was predicted using a method in clinical use. The presence of hybrid genes had no effect on the phenotype prediction of CYP2D6*4- and CYP2D6*10-containing samples. Four of four (100%) homozygous samples containing a CYP2D7-2D6 gene had a change in predicted phenotype, and 23 of 25 (92%) samples with a duplication signal and a CYP2D7-2D6 gene had a change in predicted phenotype. Four novel genes were identified (CYP2D6*13A1 variants 1 and 2, CYP2D6*13G1, and CYP2D6*13G2), and two novel hybrid tandem structures consisting of CYP2D6*13B + *68×2 + *4-like and CYP2D6*13A1 variant 2 + *1×N were observed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22004686      PMCID: PMC3250050          DOI: 10.1124/dmd.111.040832

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  25 in total

1.  New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine.

Authors:  Michihiro Chida; Noritaka Ariyoshi; Tsuyoshi Yokoi; Nobuo Nemoto; Makoto Inaba; Moritoshi Kinoshita; Tetsuya Kamataki
Journal:  Pharmacogenetics       Date:  2002-11

2.  The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations.

Authors:  Tashinga E Bapiro; Julia A Hasler; Marianne Ridderström; Collen M Masimirembwa
Journal:  Biochem Pharmacol       Date:  2002-11-01       Impact factor: 5.858

Review 3.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.

Authors:  J Kirchheiner; K Nickchen; M Bauer; M-L Wong; J Licinio; I Roots; J Brockmöller
Journal:  Mol Psychiatry       Date:  2004-05       Impact factor: 15.992

4.  The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

Authors:  Matthew P Goetz; Stacey K Knox; Vera J Suman; James M Rae; Stephanie L Safgren; Matthew M Ames; Daniel W Visscher; Carol Reynolds; Fergus J Couch; Wilma L Lingle; Richard M Weinshilboum; Emily G Barr Fritcher; Andrea M Nibbe; Zeruesenay Desta; Anne Nguyen; David A Flockhart; Edith A Perez; James N Ingle
Journal:  Breast Cancer Res Treat       Date:  2006-11-18       Impact factor: 4.872

Review 5.  The impact of CYP allelic variation on antidepressant metabolism: a review.

Authors:  John L Black; Dennis J O'Kane; David A Mrazek
Journal:  Expert Opin Drug Metab Toxicol       Date:  2007-02       Impact factor: 4.481

6.  Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.

Authors:  U M Zanger; J Fischer; S Raimundo; T Stüven; B O Evert; M Schwab; M Eichelbaum
Journal:  Pharmacogenetics       Date:  2001-10

7.  CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.

Authors:  Andrea Gaedigk; L Dianne Bradford; Sarah W Alander; J Steven Leeder
Journal:  Drug Metab Dispos       Date:  2006-01-13       Impact factor: 3.922

8.  Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.

Authors:  Werner Steimer; Konstanze Zöpf; Silvia von Amelunxen; Herbert Pfeiffer; Julia Bachofer; Johannes Popp; Barbara Messner; Werner Kissling; Stefan Leucht
Journal:  Clin Chem       Date:  2004-06-17       Impact factor: 8.327

9.  A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.

Authors:  Sebastian Raimundo; Claudia Toscano; Kathrin Klein; Joachim Fischer; Ernst-Ulrich Griese; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  Clin Pharmacol Ther       Date:  2004-08       Impact factor: 6.875

10.  Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants.

Authors:  Andrea Gaedigk; Lazara Karelia Montane Jaime; Joseph S Bertino; Anick Bérard; Victoria M Pratt; L Dianne Bradfordand; J Steven Leeder
Journal:  Front Pharmacol       Date:  2010-10-04       Impact factor: 5.810

View more
  22 in total

Review 1.  Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing.

Authors:  Yao Yang; Mariana R Botton; Erick R Scott; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2017-05-04       Impact factor: 2.533

2.  Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.

Authors:  Yuan Ji; Jennifer M Skierka; Joseph H Blommel; Brenda E Moore; Douglas L VanCuyk; Jamie K Bruflat; Lisa M Peterson; Tamra L Veldhuizen; Numrah Fadra; Sandra E Peterson; Susan A Lagerstedt; Laura J Train; Linnea M Baudhuin; Eric W Klee; Matthew J Ferber; Suzette J Bielinski; Pedro J Caraballo; Richard M Weinshilboum; John L Black
Journal:  J Mol Diagn       Date:  2016-03-03       Impact factor: 5.568

Review 3.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

4.  Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.

Authors:  Roseann S Gammal; Kristine R Crews; Cyrine E Haidar; James M Hoffman; Donald K Baker; Patricia J Barker; Jeremie H Estepp; Deqing Pei; Ulrich Broeckel; Winfred Wang; Mitchell J Weiss; Mary V Relling; Jane Hankins
Journal:  Pediatrics       Date:  2016-07       Impact factor: 7.124

5.  Identification of CYP2D6 Haplotypes that Interfere with Commonly Used Assays for Copy Number Variation Characterization.

Authors:  Amy J Turner; Praful Aggarwal; Erin C Boone; Cyrine-Eliana Haidar; Mary V Relling; Ashley D Derezinski; Ulrich Broeckel; Andrea Gaedigk
Journal:  J Mol Diagn       Date:  2021-02-22       Impact factor: 5.568

6.  Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics.

Authors:  E W Chua; M A Kennedy
Journal:  Front Pharmacol       Date:  2012-08-20       Impact factor: 5.810

7.  Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients.

Authors:  Margot A Cousin; Eric T Matey; Patrick R Blackburn; Nicole J Boczek; Tammy M McAllister; Teresa M Kruisselbrink; Dusica Babovic-Vuksanovic; Konstantinos N Lazaridis; Eric W Klee
Journal:  Mol Genet Genomic Med       Date:  2017-03-19       Impact factor: 2.183

8.  Pharmacogenetic testing revisited: 5' nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19.

Authors:  Jens Borggaard Larsen; Jan Borg Rasmussen
Journal:  Pharmgenomics Pers Med       Date:  2017-04-18

9.  Genome sequencing as a platform for pharmacogenetic genotyping: a pediatric cohort study.

Authors:  Iris Cohn; Tara A Paton; Christian R Marshall; Raveen Basran; Dimitri J Stavropoulos; Peter N Ray; Nasim Monfared; Robin Z Hayeems; M Stephen Meyn; Sarah Bowdin; Stephen W Scherer; Ronald D Cohn; Shinya Ito
Journal:  NPJ Genom Med       Date:  2017-05-26       Impact factor: 8.617

10.  CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications.

Authors:  Jennifer L St Sauver; Janet E Olson; Veronique L Roger; Wayne T Nicholson; John L Black; Paul Y Takahashi; Pedro J Caraballo; Elizabeth J Bell; Debra J Jacobson; Nicholas B Larson; Suzette J Bielinski
Journal:  Pharmgenomics Pers Med       Date:  2017-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.